Radiation recall dermatitis after oral cyclophosphamide

peer reviewedRadiation recall dermatitis is an inflammatory skin reaction occurring in a previously irradiated field following the delivery of a promoting agent. It has been described after a number of antineoplastic agents such as gemcitabine, taxanes, anthracyclines. We report the case of a 50-year-old man with metastatic prostate cancer who developed two consecutive radiation recall dermatitis episodes triggered by oral cyclophosphamide. They occurred 4 to 5 weeks after palliative radiotherapy on bone metastasis. Spontaneous resolution was observed within 6 weeks after discontinuation of cyclophosphamide and with local supportive care. To our knowledge this is the first reported case of radiation recall dermatitis after oral cyclophosphamide

Primary and Secondary Prevention of Colorectal Cancer

peer reviewedColorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed, particularly by aspirin and non steroidal anti-inflammatory drugs. Development of specific cyclooxygenase-2 inhibitors constitutes a promising research's field. Secondary prevention by coloscopy and polypectomy must lead to a lower rate of colorectal cancer disease and improvement of mortality

Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study.

peer reviewedBACKGROUND: The spread of the COVID-19 pandemic has led to a rapid reorganization in all human and hospital activities, with impact on cancer patients. AIM: An analysis of cancer patients fears, and awareness of COVID-19 has been done in this study. METHODS AND RESULTS: We analyzed cancer patients' reactions to the pandemic and their perception of oncological care reorganization, through a 12-item survey, proposed at the peak of pandemic and 3 months later. Overall, 237 patients were included in the study. During the peak of pandemic 34.6% of patients were more worried about COVID-19 than cancer versus 26.4% in the post-acute phase (p = .013). Although 49.8% of patients in the acute phase and 42.3% in the post-acute phase considered their risk of death if infected ≥50%, and more than 70% of patients thought to be at higher risk of complications, the majority of them did not consider the possibility to stop or delay their treatment. Patients were more interested in following news about COVID-19 than cancer and they complied with all preventive measures in more than 90% of the cases. CONCLUSIONS: Although cancer patients worried about COVID-19 and evaluated the risk of complication or death due to COVID-19 as extremely high, they were still asking for the best oncological treatment

New treatments for castration-resistant prostate cancer

peer reviewedDocetaxel chemotherapy is a standard treatment for fit men with symptomatic castration-resistant prostate cancer. Unfortunately docetaxel resistant disease will systematically develop and second-line treatment may be appropriate. Until recently no standard treatment was approved in this setting and mitoxantrone was commonly used. Three new drugs have shown benefit in randomised phase 3 multicenter clinical trials published since 2010. Cabazitaxel, abiraterone and enzalutamide were shown to prolong overall survival of men with metastatic castration-resistant prostate cancer previously treated with chemotherapy. Although still modest these results were deemed clinically significant and led to the reimbursement of Jevtana (cabazitaxel) and Zytiga (abiraterone) in Belgium in 2012

L'image du mois. Une image de "lâcher de ballons" à l'imagerie thoracique

peer reviewe

Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene

[No abstract available

Apalutamide, Erleada®

editorial reviewe

Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique

editorial reviewedProstate cancer treatment relies on a multimodal approach based on the patient and disease characteristics. In this regard, imaging plays a crucial role in assessing cancer, whether it is for the initial evaluation or when recurrence occurs. Once it becomes metastatic (either at diagnosis or after curative treatment), castration, whether surgical or medical, used to be the sole treatment for these patients. However, since the introduction of chemotherapy with docetaxel and the emergence of next-generation hormone therapies such as abiraterone, enzalutamide, apalutamide and darolutamide, their survival has been significantly improved. In addition to these systemic treatments comes the possibility of irradiating the prostate tumor in patients with low-volume metastatic disease. After several months or years, these patients inevitably progress to the lethal form of the disease: castration-resistant prostate cancer. In this context, besides docetaxel, abiraterone, and enzalutamide, other treatments are also available, such as cabazitaxel, DNA repair-targeting agents like PARP inhibitors, radium-223, or more recently, Lu-PSMA. In some cases, a combination of treatments may also be considered. The objective of this review is to examine the role of imaging in the initial staging and metastatic recurrence work-up of prostate cancer, as well as the various therapeutic strategies for hormone-sensitive and castration-resistant metastatic prostate cancer